Follow-The-Filings

Security · featured owners

PTGX Protagonist Therapeutics Inc.

Health Care COM Equity as of 2026 Q2 among managers we track

  • 5 Owners
  • Max 3.6%
  • $821M
  • 2 add 1 reduce

PTGX (Protagonist Therapeutics Inc.) is held in 5 featured 13F books as of 2026 Q2. Farallon Capital Management is the largest tracked holder by portfolio weight (3.6%). Figures are as-filed 13F, not free float.

Who owns this now

Largest portfolio weights among featured holders · max 3.6% (Farallon Capital Management) · not free-float ownership

  1. Farallon Capital Management 3.6%
  2. James Silverman 1.1%
  3. Stanley Druckenmiller Add 0.49%
  4. Polen Capital Management Reduce 0.02%

Holders

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

History
Farallon Capital Management 2026 Q2 3.6% Hold 6,348,906 $778M History
Stanley Druckenmiller - Duquesne Family Office 2026 Q2 0.49% Add +30.8% 208,900 $26M History
James Silverman - Opaleye Management 2026 Q2 1.1% Hold 100,000 $12M History
Polen Capital Management 2026 Q2 0.02% Reduce −6.9% 22,651 $3M History
Ron Baron - Bamco Inc. (Baron Capital) 2026 Q2 <0.01% Add +6.7% 16,000 $2M History

5 current · options excluded

SEC filings

Recent issuer filings from EDGAR · 8 shown · open Filing / Doc on SEC.gov

Filed Form Detail Links
8-K 2.02,7.01,9.01 Filing Doc
10-Q Filing Doc
8-K 5.02,5.07,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEFA14A Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc

Insider forms

Form 3 / 4 / 5 from EDGAR · 20 rows shown

Filed Form Detail Links
4 Period Sep 8, 2026 Filing Doc
4 Period Sep 3, 2026 Filing Doc
4 Period Aug 10, 2026 Filing Doc
4 Period Jun 23, 2026 Filing Doc
4 Period Jun 10, 2026 Filing Doc
4 Period May 29, 2026 Filing Doc
4/A Period May 12, 2026 Filing Doc
4 Period May 12, 2026 Filing Doc
4 Period May 7, 2026 Filing Doc
4 Period Apr 23, 2026 Filing Doc
4 Period Apr 20, 2026 Filing Doc
4 Period Mar 26, 2026 · 3 forms Filing Doc
4 Period Mar 23, 2026 Filing Doc
4 Period Feb 17, 2026 Filing Doc
4 Period Feb 6, 2026 Filing Doc
4 Period Jan 23, 2026 Filing Doc
4 Period Jan 27, 2026 Filing Doc
4 Period Jan 23, 2026 Filing Doc
4 Period Jan 20, 2026 · 3 forms Filing Doc
4 Period Jan 9, 2026 Filing Doc

Updated 17 days ago Source: SEC EDGAR submissions All on EDGAR

Financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Net income -$78.96M $275.19M -$130.15M

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $355.58M $591.64M $577.57M
Total non-current assets * $2.37M $153.08M $90.61M
Total assets $357.95M $744.72M $668.19M
Total current liabilities $21.27M $47.4M $45.44M
Total non-current liabilities * $0M $22.03M $8.04M
Total equity $336.68M $675.3M $614.71M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$70.24M $184.15M $57.67M
Cash from investing -$39.26M -$299.48M -$49.33M
Cash from financing $170.48M $25.85M $22.86M
Net change in cash $60.98M -$89.48M $31.2M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

Ownership over time

filing count by report period · click a bar for that quarter’s holders